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Abstract
Purpose Minimally invasive parathyroidectomy (MIP) is the
recommended treatment in primary hyperparathyroidism
(pHPT) for which accurate preoperative localization is essen-
tial. The current imaging standard consists of cervical ultraso-
nography (cUS) and MIBI-SPECT/CT. 11C-MET PET/CT has
a higher resolution than MIBI-SPECT/CT. The aim of this
study was to determine the diagnostic performance of 11C-
MET PET/CTafter initial inconclusive or negative localization.
Methods We performed a retrospective single center cohort
study of patients with pHPT undergoing parathyroid surgery
after prior negative imaging and later localization by means of
11C-MET PET/CT between 2006 and 2014. Preoperative local-
ization by 11C-MET PET/CTwas compared with later surgical
localization, intraoperative quick PTH (IOPTH), duration of
surgery, histopathology, and follow-up data. Also, differences
in duration of surgery between the groups with and without
correct preoperative localization were analyzed.
Results In 18/28 included patients a positive 11C-MET-PET/CT
result corresponded to the surgical localized adenoma (64%). In
3/28 patients imaging was false positive and no adenoma was
found. In 7/28 patients imaging was false negative at the side of
the surgically identified adenoma. Sensitivity of 11C-MET PET/
CTwas 72% (18/25). Duration of surgery of correctly localized
patients was significantly shorter compared to falsely negative
localized patients (p = 0.045).
Conclusion In an intention to treat 11C-MET-PET/CTcorrect-
ly localized the parathyroid adenoma in 18/28 (64%) patients,
after previous negative imaging. A preoperatively correct lo-
calized adenoma leads to a more focused surgical approach
(MIP) potentially reducing duration of surgery and potentially
healthcare costs.
Keywords Minimally invasive parathyroidectomy (MIP) .
Primary hyperparathyroidism (pHPT) . 11C-methionine
positron emission tomography (11C-METPET)
Introduction
Primary hyperparathyroidism (pHPT) is a common endocrine
disorder, with the highest incidence in elderly women [1]. It
occurs sporadically, but is also associated with hereditary syn-
dromes such as multiple endocrine neoplasia (MEN) type 1
and 2. pHPT is characterized by hypercalcemia in the presence
of high concentrations of PTH, which can lead to abdominal
complaints, osteoporosis, kidney stones, muscle weakness,
pain, depression and behavioral changes.
Surgery is the only curative and recommended treatment in
patients with pHPT usually by means of a minimally invasive
parathyroidectomy (MIP). In MIP, surgeons remove the ade-
noma via a unilateral approach with a minimal invasive inci-
sion of 1–2 cm. In 80 to 90% of the pHPT cases, only a single
parathyroid adenoma is present, making this surgical strategy
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usually successful [2]. However, to be able to perform a uni-
lateral MIP, accurate preoperative imaging is essential.
Worldwide, the current primary preoperative localization
imaging standard consists of cervical ultrasonography (cUS)
combined with 99mTc-methoxyisobutylisonitrile single-
photon emission computed tomography/computed tomogra-
phy (MIBI-SPECT/CT) [3, 4]. Planar MIBI scintigraphy has
the lowest sensitivity, around 70% [5, 6], performing better
when combined with SPECT/CT [5].
However, although better, even MIBI-SPECT/CT alone is
not optimal with a sensitivity of 85% [5, 7–13]. But when the
MIBI-SPECT/CT is combined with cUS (sensitivity from 22
to 82%) [2, 9–11] a sensitivity of 80–90% can be achieved
[14–16]. This means that using these two modalities still in
10–20% of the cases, the surgeon will not be able to schedule
the patient for a focused MIP operation.
11C-methionine positron emission tomography/CT
(11C-MET PET/CT) is a nuclear imaging technique that
can be used as a next step for imaging after prior negative
localization. C-methionine accumulates in the parathyroid
adenoma and is involved in the synthesis of the precursor
of PTH [17–19]. It improves the detection performance of
parathyroid tissue due to a better spatial resolution of PET/
CT [20]. When 11C-MET PET/CT became available in
2006 at our institute, we used this nuclear imaging modal-
ity as a step up approach after inconclusive imaging.
The aim of this study was to determine the diagnostic
performance of 11C-MET PET/CT after prior negative locali-
zation in patients with pHPT.
Material and methods
This is a retrospective single center cohort study of patients
with biochemically proven pHPTwho underwent parathyroid
surgery after localization bymeans of a 11C-METPET/CT in a
teaching and tertiary referral hospital.
Patients
The medical charts of all patients who underwent 11C-MET
PET/CT between January 2006 and December 2014 were
reviewed. To be eligible for inclusion, patients had to be older
than 18 years and had to have a biochemically confirmed
pHPT, for which parathyroid surgery was planned. A MIBI-
SPECT/CT and/or cUS had to have been performed, however
with negative or inconclusive result, after which patients
underwent a 11C-MET PET/CT. Patients were excluded if
they were known to have a germline mutation predisposing
for multiple gland disease or if an alternative diagnosis (e.g.,
parathyroid carcinoma) was known before surgery.
The medical charts were reviewed to determine the out-
come of the imaging tests (negative = no localization stated
in the original report, inconclusive = an original report de-
scribing a presumed adenoma with doubt), or positive = orig-
inal reports describing the location of the presumed adenoma
without any doubt). Also, data on gender, age, preoperative
PTH, corrected calcium, intraoperative quick PTH (IOPTH),
previous parathyroid surgery, the length of surgery and pathol-
ogy outcome were collected. Corrected calcium was calculat-
ed using the following formula: Ca + ((40 – Alb) × 0.02).
BCa^ is the serum calcium (mmol/l) and BAlb^ is the serum
albumin (g/l). The diagnosis pHPTwas made by experienced
endocrinologists from our center and all the patients were
discussed in a multidisciplinary endocrine board.
Data obtained from patient records were anonymously stored
using study-specific patient codes in a password protected data-
base. The local ethical board evaluated the study and according
to Dutch law, no additional review board approval was required.
cUS
cUS was performed in a number of different hospitals on var-
ious ultrasound systems. All patients who underwent cUS were
examined in a supine position with a hyperextended neck using
a high-frequency linear transducer, as is common practice. The
neck was always examined from the level above the thyroid to
the clavicle caudally. Findings suggestive for parathyroid ade-
nomas were documented in two planes with special regard to
size and anatomic correlation to adjacent structures.
MIBI-SPECT/CT
Between 2006 and 2014, parathyroid imaging was performed
with various protocols due to changes in gamma cameras and
radiotracers. Also, some procedures were performed in other
hospitals according to slightly different imaging protocols.
However, all protocols adhered to the international guidelines
[21]. At the UniversityMedical Center Groningen (UMCG) until
2010, images were performed using aMultispect 2 gamma cam-
era (Siemens), on which only SPECT images could be made.
Afterwards, patients were scanned on a Symbia T16 gamma
camera with CT (Siemens), resulting in SPECT/CT images.
Furthermore, always 99mTechnetium (99mTc)-sestamibi (MIBI)
was used for preoperative localization as Bdual phase^ technique.
This technique was always combined with a Bdual tracer^ sub-
traction technique for thyroid only visualization, although a
switch in tracer was made in 2012, and 123I was replaced by
99mTc-pertechnetate. Thus, currently theMIBI-SPECT/CT imag-
ing protocol includes early and late planar MIBI images com-
bined with 99mTc-pertechnetate planar subtraction images, and
late MIBI SPECT/CT 3D images.
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11C-Met Pet/CT
In the current study, two PET cameras were used. Patients
were either scanned on a Ecat EXACTHR + PETonly system
or a PET/CT (Biograph mCT, 64 slice CT) camera (in use
since October 2009) (both Siemens) and had to fast for 6 h
while drinking 1 l of water prior to the PET procedure. PET
images were taken 20 min after injection of 7 MBq/kg 11C–
methionine which was produced on site as described by Phan
et al. [22]. The head and neck area was scanned in two bed
positions (2D imaging, 7 min per bed position and 2 min
transmission scan) using the HR + camera, while it was
scanned in three bed positions using the mCT camera (3 min
per bed position, prior low dose CT for attenuation correction;
100 kV, 30 Quel Ref mAs, 1.5 pitch). PET images were iter-
atively reconstructed using four iterations, 16 subsets with a
5 mm Gausian filter for HR+, and using three iterations, 21
subsets with 4 mm Gausian filter for mCT. Low dose CT
images were reconstructed with 2 mm slice thickness.
Surgery All the surgical procedures were performed by the
same three experienced surgeons.
Generally, the focused approach utilized was a mini-
incision procedure involving a 2- to 3-cm keyhole incision
either laterally at the medial edge of the sternocleidomastoid
muscle or centrally, depending on the surgeon’s preference.
The aim of the operation was to identify and remove a para-
thyroid adenoma concordant with the MET-PET imaging, and
the ipsilateral gland was not routinely examined.
Failure to locate an adenoma, or an incidental finding of two
enlarged ipsilateral glands, would prompt conversion to bilateral
4-gland exploration. IOPTH was measured at T0 (incision), T1
(after removal of adenoma), T2 (+5 min), T3(+5 min) and T4
(+5 min). A successful procedure (final outcome) was defined as
a decrease of the IOPTHof at least 65% in the surgical report and
the finding of parathyroid tissue in the pathology report. Data on
how the surgical procedure was performed, were reviewed by an
independent endocrine surgeon unaware of the outcome.
Furthermore, final localization of the adenoma during surgery
was based on the anatomic description in the surgical report.
Follow-up data at 6 months postoperatively were collected (for
overall cure rate) to determine if patients were cured or still
experienced pHPTwith symptoms.
Preoperative adenoma localization by 11C–MET-PET/CT
was defined as true positive, true negative, false positive, and
false negative, dependent on the final outcome. The final out-
come was based on the surgical and pathology report.
Suspected adenomas localized to the correct side (left or right)
on the basis of surgical and pathologic findings were scored as
true positive. Suspected adenomas localized to the incorrect
side were scored as false positive. Sensitivity of 11C–MET-
PET/CT was calculated as the number of true positive scans
divided by the true positive and false negative scans, at a
patient level. The duration of surgery in minutes (min) was
determined per group, depending on the 11C-MET PET/(CT)
results.
Statistics
Data were analyzed using descriptive statistics on a patient
based level. Mean (± SD) or median with range were calcu-
lated when appropriate. Differences between duration in sur-
gery in different groups were calculated using a Mann-
Whitney U test. Categorical variables were expressed in pro-
portions. SPSS version 22 statistical software was used. A p
value of <0.05 was considered significant.
Results
Patients
In total, 65 patients underwent a parathyroid 11C-MET PET/
CT between January 2006 and December 2014. Of these 65
patients, 28 patients were included in this analysis. Patients
were not eligible for inclusion because of age < 18 years
(n = 1), tertiary HPT (n = 2), preoperative diagnosis of a
parathyroid carcinoma (n = 6), patients with a known MEN
2a syndrome (n = 3), 1 patient with a lithium based HPT, and 1
patient with familial hypocalciuric hypercalcemia (FHH). An
additional 15 patients were excluded because they were not
operated. These were patients who did not meet criteria for
surgery according to the guidelines (n = 9) [3], or patients in
whom surgery was deferred due to health risks or the wish of
the patient (n = 6). Eight patients were referred to our hospital
solely for the 11C-MET PET/CT and treatment and other clin-
ical data were not available. Of the 15 patients not referred for
surgery, 11C-MET PET/CT was negative in 11 patients.
Thus, 28 patients were included in this study of which 22
were female. Median age was 68 years (23–84). Patients’
baseline characteristics are depicted in Table 1, including in-
dications for surgery according to the guidelines [3].
Table 2 shows the results of the preoperative localization
techniques and results, the intraoperative findings, and find-
ings on pathology and final diagnosis. A cUS was performed
in 16 of the 28 patients, of which in 10 patients the cUS was
performed outside our center. Of these cUS, in 3 patients the
results are unknown. In 7 of the remaining patients the cUS
did not show an adenoma (negative), in 6 patients results were
inconclusive.
MIBI-SPECT/CTwas performed in all 28 patients. Twelve
patients underwent MIBI-SPECT/CT according to the old
protocol (late 123I images subtracted from the early 99m Tc-
sestamibi), while 8 patients underwent MIBI-SPECT/CT ac-
cording to the current protocol (99mTc-pertechnetate images
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subtracted from the early 99mTc-sestamibi images), and in the
other 8 patients, MIBI-SPECT/CTwas performed outside our
center. MIBI-SPECT/CT was negative in 18 patients and in-
conclusive in 9 patients. In 1 patient, MIBI-SPECT/CT was
negative at first, but after revision at the time of 11C-MET
PET/CT, theMIBI-SPECT/CT images were scored as positive
on the left side.
11C-MET PET/CT and surgical results
Table 3 shows the results of the final outcome compared with
the preoperative localization by 11C-MET PET/CT. The HR +
camera (PETonly) for 11C-MET PETwas used in 11 patients.
The mCT PET/CT camera was used in 17 patients. 11C-MET
PET/CTwas positive in 21 patients and negative in 7 patients.
Figure 1 shows an example of a patient (number 1) with a
negative MIBI-SPECT/CT and a positive 11C-MET PET/CT.
11C-MET PET/CTwas true positive in 18 of the 28 patients
(64%) (6 on the left side, 11 right side). In 1 patient, 11C-MET
PET/CT was positive bilaterally, but during surgery the ade-
noma was localized on the left side.
In 3 of the 28 patients, 11C-MET PET/CT was positive,
while the surgeon could not locate the adenoma during sur-
gery. In 2 of these 3 patients, imaging was positive on the right
side and in 1 patient imaging was positive bilaterally. These 3
patients were all diagnosed with persistent mild hyperparathy-
roidism during follow-up for which no medical treatment
(specifically cinacalcet), was deemed necessary. In one
Table 1 Patients’ baseline characteristics









1 F 41 13.0 2.62 2 Y RBD, Age, Symp
2 F 67 31 2.79 2 Y Ca, RBD, Symp
3 M 71 179 3.94 3 N Ca, GFR, Symp
4 F 66 18.0 3.06 1 Y Ca, RBD, Symp
5 F 84 121.0 3.30 2 Y Ca, GFR, Symp
6 M 68 12.0 2.63 2 N RBD, Symp
7 F 73 21.0 2.96 2 N Ca, RBD
8 F 46 19.0 2.58a 1 N Age, RS, Symp
9 M 62 27.0 2.98 2 Y Ca
10 F 51 12.0 2.75 3 N Ca
11 F 79 34.0 3.23 2 Y Ca, Symp
12 M 71 8.6 2.72 3 N RS, Symp, Ca
13 F 68 48.0 2.64 2 N Symp
14 F 72 22.0 2.83 1 N RBD, Symp, Ca
15 F 65 44.0 3.11 2 N Ca, RS, Symp
16 F 60 50.0 2.94 2 Y Ca, Symp
17 F 23 9.8 2.63 2 N Age, RS, Symp
18 F 53 16.0 2.72 3 N Ca, Symp
19 M 72 29.0 2.98 2 N RBD, Ca, Symp
20 F 76 24.0 2.69 2 Y RBD, Symp
21 F 81 16.0 2.72 3 N Ca, Symp
22 F 64 10.0 2.66 2 Y Ca, Symp
23 M 52 7.2 2.63 1 N RS, Symp
24 F 33 21.0 2.71 2 N Ca, RBD, Symp
25 F 71 16.0 2.93 2 Y Ca, RS, RBD, Symp
26 F 72 62.0 3.66 1 N GFR, Symp, Ca
27 F 81 19.0 2.74 2 N GFR, Ca, Symp
28 F 62 17.0 2.82 1 N Ca, Symp
F female,Mmale, Y yes,NNo, RBD reduction bone density (women/men >50 with a T score of ≤2.5 at the lumbar spine, femoral neck, total hip, or 33%
radius. Women/men <50 with a Z score ≤2.5), Age age younger than 50 years, Symp symptoms, Ca elevated calcium (>0.25 mmol/l above the upper
limits of normal), GFR GFR <60 ml/min 1.73 m2, RS renal stones
a This patient showed an elevated calcium excretion in a different hospital. Also, we assume that serum calcium was most elevated at time of diagnosis.










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































patient, accidentally a papillary thyroid carcinoma was found
in the pathology specimen. This may have caused the false
positive 11C-MET PET/CT [22]. Even after completion of
thyroidectomy, the (mild) hyperparathyroidism still persisted
and a parathyroid adenoma was never found. [22].
In the remaining 7 patients, 11C-MET PET/CT was false-
negative at the side where the surgeon located the adenoma. In
these patients, the surgeon did not perform a focused ap-
proach, but a unilateral or bilateral neck exploration. In 6/7
patients imaging was negative, but during surgery the adeno-
ma was found on one side (two on the left, four right). In 1/7
patients imaging was positive on the left side, but during sur-
gery, the adenoma was found on the contralateral side.
In the 25 patients with positive surgery, IOPTH showed a
decrease of at least 65% in 23 patients. In two patients the
IOPTH was not performed, because these patients were oper-
ated outside our center, while pre-operative imaging and
follow-up was performed in our center.
The sensitivity of 11C-MET PET/CT calculated at a patient
level was 72% (18/25).
Of the 18 true positive findings, surgeons explored unilat-
erally in 12 patients, bilaterally in 4 patients and in 2 patients
data is unknown. Of the 7 false negative findings, surgeons
explored unilaterally in 2 patients and bilaterally in 5 patients.
In the 3 false positive findings, surgeons explored unilaterally
in 1 patient and bilaterally in 2 patients.
In 25 (18 true positive +7 false negative) patients, the sur-
geon found a suspected adenoma. Histopathology confirmed a
parathyroid adenoma in 24 patients and in 1 patient histopa-
thology confirmed an accidentally found parathyroid carcino-
ma (Table 2).
Of the 25 patients with positive surgery, 25 were cured and
did not experience symptoms during follow-up resulting in an
overall cure rate of 86% (24/28) as one patient was lost during
follow-up (Table 2).
Duration of surgery
A significant difference was present in the duration of surgery
between patients with a true positive 11C-MET PET/CT com-
pared to patients with a false negative 11C-MET PET/CT. True
positive patients spend amedian time of 194 min (128–281) in
the operation room, while false negative patients spend a me-
dian time of 237 min (190–269) in the operation room
(p = 0.045).
Discussion
This retrospective single center cohort study evaluates the
diagnostic performance of 11C-MET PET/CT after prior
non-conclusive localization via MIBI-SPECT/CT and/or
Table 3 Final outcome of surgery and pathology combined compared
with results of 11C-MET PET/CT
Surgery + Pathology
11C-MET PET/CT Positive Negative
Positive 18 3
Negative 7 0
Fig. 1 Patient example of a negative MIBI-SPECT/CT and a positive
11C-MET PET/CT. Planar anterior image of the neck with 99mTc-
pertechnetate (a), early 99mTc-MIBI (b), and late 99mTc-MIBI (c). Both
planar subtraction image (early 99mTc-MIBI minus 99mTc-pertechnetate
image (d)) and 99mTc-MIBI SPECT-CT (E1-SPECT image only and E2
fused SPECT/CT image) do not show a clear focus suspect for adenoma.
The 11C-MET PET/CT showed a small lesion located caudally from the
left thyroid gland, suspicious for parathyroid adenoma (red arrow F1-
PET image only and F2-fused PET/CT image)
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cUS in patients operated for biochemically confirmed pHPT. In
this challenging clinical setting, 11C-MET PET/CT was able to
adequately localize the adenoma correctly in nearly two-third of
the patients. Thus, in these patients the surgeonwas subsequently
able to perform a successful focused approach.
We found that 11C-MET PET/CT in this series localized the
adenoma in 64% at the correct side of the neck. In 3 patients,
the 11C-MET PET/CT was false positive, and the surgeon
could not locate an adenoma. Reasons for false positivity
might be benign and malignant thyroid lesions, as was the
case in one of our patients [22].
Although few studies describe the diagnostic performance
of 11C-MET PET/CT, our sensitivity of 72% is comparable
with earlier studies. Beggs et al. who included 51 patients,
found a sensitivity of 83% [23]. In Beggs et al., also patients
in whom other imaging techniques such as MIBI scanning,
CT, or ultrasound had earlier failed to localize the adenoma
were selected. In a recent smaller study with 18 patients,
Braeuning et al. found a sensitivity per patient of 91.7% and
a sensitivity per lesion of 73.3% after a prior negative 99mTc-
MIBI-SPECT/CT [24]. Another smaller study by Chun et al.
who included 16 patients found a sensitivity of 91.7%, but did
not select patients with prior negative imaging [20]. Traub-
Weidinger et al. included 15 patients with negative 99mTc-
MIBI SPECT/CT and earlier neck surgery because of pHPT
and/or thyroid disorder and found a sensitivity of 40% [25].
With a sensitivity of 40% for 11C-MET PET/CT, these results
differ from other studies. The varying surgical history of the
patients in this series may be an explanation [25]. Martinez-
Rodriguez et al. included 14 patients in a prospective study
and showed a sensitivity of 76.9%, but only 2 patients had
previous neck surgery [26]. Additionally, no patients with
prior negative imaging were selected. So, with 28 included
patients (10 with previous neck surgery) this is one of the
largest studies reflecting the performance of 11C-MET PET/
CT in patients with pHPT after prior negative imaging.
We realize that our retrospective study has limitations. In
this study, only patients were included who had undergone
11C-MET PET/CT and were subsequently surgically treated.
Correspondingly, of the 15 patients not referred for surgery,
11C-MET PET/CT was negative in 11 patients. This referral
bias may have led to overestimation of the sensitivity of the
11C-MET PET/CT. However, our study group also included
patients with negative results of 11C-MET PET/CT that
underwent surgery. Also, performance of MIBI-SPECT/CT
highly depends on the protocol used. If all patients would have
received a dual phase MIBI-SPECT/CT, more adenomas could
have been localized and in the remaining patients, adenomas
might have been harder to localize. This may also have led to
some overestimation of the performance of 11C-MET PET/CT.
In this study, the results of surgery were seen as the gold
standard, which could be a drawback of the current analysis.
Although a surgical neck exploration is technically protocolled,
heterogeneity in surgical techniques remains inevitable. Also,
in this study imaging procedures changed slightly during the
years, which might have influenced our results.
The strong point of our study is that it describes and reflects
the strategy of preoperative 11C-MET PET/CT after earlier
negative imaging. The success of a focused approach strongly
depends on how well the adenoma is localized by imaging
preoperatively.
In this series duration of surgery is relatively long, since
anesthesiology and waiting time for IOPTH was included and
the data were gathered in a tertiary referral hospital which adds
to more extended surgery times because of a patient selection
for more difficult cases. Furthermore, we conduct a training
program for residents and therefore also provide surgical train-
ing during operations which required time because of learning
curve. Most importantly however, if 11C-MET PET/CT cor-
rectly located the adenoma, the duration of surgery was sig-
nificantly shorter.
In general, preoperative localization saves operation time
because of a double effect. Firstly, operating via keyhole sur-
gery is a shorter and more effective procedure compared to an
open bilateral exploration and secondly the surgeon knows
where the adenoma should be located. Furthermore, if the
surgeon finds the adenoma where it was expected to be, often
less perioperative adjuncts such as IOPTH are needed, also
shortening the procedure. Finally, when the patient is in-
formed about the small risk of having a 5% chance of a second
adenoma, a second contralateral procedure in the future will
still be in a surgical virgin territory and therefore is an accept-
able calculated risk. We speculate that eventually in the long
run, this might lead to a decrease in healthcare costs. More
research on this topic is mandatory.
Globally, cUS andMIBI-SPECT/CTare used first in line to
localize parathyroid adenomas being relatively cheap and
widely available imaging techniques [3, 4]. Replacing cUS
andMIBI-SPECT/CTwith 11C-MET PET/CT is not a realistic
option. 11C-MET PET/CT has a more complicated radio-
chemistry tracer production, includes the need for a cyclotron
on site, and has significantly higher costs.When available, it is
therefore more realistic to use 11C-MET PET/CT as a step up
approach only after earlier negative localization by MIBI-
SPECT/CT and/or cUS.
Other various imaging protocols in the detection of a para-
thyroid adenoma are also feasible. For example, four-
dimensional computed tomography (4DCT) is another report-
ed strategy as a next step imaging procedure, because of its
high sensitivity (88%) [27, 28]. Choline PET, known from its
use in prostate cancer diagnostics, can either be performed
with 11C–choline or 18F–choline and may be a good imaging
alternative for 11C-MET PET/CT. First results in literature
look promising [9, 29, 30], however, results comparing the
two tracers directly are not available. Also, in this area more
research is warranted. Furthermore, a cost-effectiveness
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analysis on the various anatomical and nuclear imaging tech-
niques and the order in which to use them in the setting of
pHPT could also be performed.
Conclusion
In conclusion, this retrospective analysis shows 11C-METPET/
CT to be a sensitive method for the localization of parathyroid
adenomas in patients with clinically suspected pHPT (sensitivity
of 72%). 11C-MET PET/CTcorrectly detects parathyroid adeno-
mas in 64% of operated patients after prior negative MIBI-
SPECT/CT and/or cUS. Since 11C-MET PET/CT is able to ad-
ditionally localize adenomas, resulting in more patients who can
be operated via MIP, the duration of surgery and thus healthcare
costs potentially decrease.
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